In response to activating stimuli, IKK is activated by the degradation IκBα, a cytoplasmic inhibitor, to allow its activation of NF-κB, and activated NF-κB then promotes cellular resistance to cancer treatments [22,23]. This evidence concerns the gene NFKB1 and cancer.